Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A greater proportion of this population than previously thought could stand to benefit from pre-exposure prophylaxis.
Tenofovir alafenamide is an updated version of tenofovir disoproxil fumarate that is tied to better bone and kidney health.
Researchers believe that in addition to producing antibodies against the virus, vaccines must also give rise to a cellular immune response.
Large trial of HIV vaccine finds it does not prevent HIV
Reduction in community-level viral load predicts HIV transmission decline
A clinical trial compared injectable cabotegravir given every eight weeks versus daily Truvada for HIV prevention.
Gilead Sciences provides the funds through its TRANScend initiative; Destination Tomorrow in the Bronx distributes them.
Mathematical models show that HIV gains in sub-Saharan Africa could be lost, say UNAIDS and WHO.
The bilingual “How Low Can You Go?” campaign offers “life-changing news” for more than 6,400 residents.
Merck’s investigational antiretroviral is a reverse transcriptase¬ translocation inhibitor.
Researchers found women are less likely than men to accept a prescription for post-exposure prophylaxis after an assault.
Experts recommend that everyone should wear cloth face masks in public.
The CDC has issued a report detailing considerations for clinicians prescribing PrEP for this population.
A rundown of POZ’s reporting on the 2020 Conference on Retroviruses and Opportunistic Infections
Researchers broke down PrEP use and HIV diagnosis data by state to analyze connections between them.
A survey of local health departments reveals concerning news—and a silver lining.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.